ContributorsPublishersAdvertisers

Ocugen Partner, Bharat Biotech, Announces Positive Immunogenicity and Safety Data from COVID-19 Candidate Vaccine

MyChesCo
MyChesCo
 15 days ago
Cover picture for the article

MALVERN, PA — Ocugen, Inc. (Nasdaq: OCGN) has announced that its partner, Bharat Biotech, posted results from a Phase 2/3 trial conducted in India of candidate vaccine, COVAXIN™ (BBV152), in children, aged 2 – 18 years, demonstrating a robust neutralizing antibody response and favorable safety profile on the pre-print server, medRXiv....

www.mychesco.com

Comments / 0

Comments / 0